Biosimilar Medicare Part B Payment Boost Begins

October 03, 2022

Under the Inflation Reduction Act, there is a 5-year temporary increase in the add-on payment for qualifying biosimilars whose average sales price (ASP) is not more than the price of the reference product.

BioRationality: a Dr Sarfaraz Niazi Column—The EMA Declares Biosimilars Interchangeable
Biosimilars Oncology Roundup for September 2022—Podcast Edition
Biosimilars Oncology Roundup: September 2022
FDA Approves Celltrion Biosimilar for Avastin, Vegzelma